Unbuzzd Wellness Inc., the licensee of Quantum BioPharma Ltd., will host an investor webinar on September 16, 2025, to discuss the company's scientifically proven beverage designed to accelerate alcohol metabolism. The event will feature CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David presenting clinical data and outlining investment opportunities. The webinar will focus on the current Reg D 506(c) investment opportunity for unbuzzd(TM), a beverage clinically shown to restore mental clarity and reduce hangover symptoms while accelerating alcohol metabolism.
Company executives will detail strategies to accelerate direct-to-consumer, distributor, and retail sales of the product, which represents a significant advancement in alcohol-related wellness solutions. Quantum BioPharma, which invented unbuzzd(TM) and spun out its over-the-counter version to Unbuzzd Wellness, retains substantial financial interest in the product's success. According to the licensing agreement, Quantum BioPharma maintains 20.11% ownership of Unbuzzd Wellness as of March 31, 2025, and receives royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also retains full rights to develop similar products for pharmaceutical and medical applications.
The investor presentation holds significance for both companies' stakeholders as Unbuzzd Wellness seeks to expand market penetration of its alcohol metabolism beverage. Quantum BioPharma continues to focus on its core biopharmaceutical research through subsidiary Lucid Psycheceuticals Inc., developing Lucid-MS for multiple sclerosis treatment while maintaining strategic investments through FSD Strategic Investments Inc. Additional company information is available through its newsroom at https://ibn.fm/QNTM.
